Custom cancer vaccine trial seeks to Re-Train immune system
NCT ID NCT07334574
Summary
This early-stage study is testing a new, personalized mRNA vaccine (XP-006) for safety and early signs of effectiveness. It is for adults with B-cell non-Hodgkin's lymphoma that has returned or not responded to prior treatments. The vaccine is designed to teach the patient's own immune system to recognize and fight their specific cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
Shanghai, 200020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.